Clinical Trial Update: Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of cadonilimab plus nab-paclitaxel for recurrent or metastatic muscle-invasive bladder cancer (bladder cancer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Cadonilimab
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Bladder Cancer | Phase 2 | Status: UNKNOWN